Rituximab for idiopathic membranous nephropathy, Lancet, vol.360, pp.923-924, 2002. ,
Rituximab therapy for membranous nephropathy: A systematic review, Clin J Am Soc Nephrol, vol.4, pp.734-744, 2009. ,
Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study, Am J Nephrol, vol.33, pp.461-468, 2011. ,
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients, Clin J Am Soc Nephrol, vol.4, pp.1083-1088, 2009. ,
Rituximab in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1416-1425, 2012. ,
Human idiopathic membranous nephropathy-a mystery solved?, N Engl J Med, vol.361, pp.81-83, 2009. ,
Latest treatment strategies for membranous nephropathy, Expert Opin Pharmacother, vol.8, pp.3159-3171, 2007. ,
Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies, N Engl J Med, vol.346, pp.2053-2060, 2002. ,
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, vol.361, pp.11-21, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00417718
, J Am Soc Nephrol, vol.26, pp.2545-2558, 2015.
Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy, J Am Soc Nephrol, vol.22, pp.1400-1402, 2011. ,
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy, N Engl J Med, vol.364, pp.616-626, 2011. ,
HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.9, pp.335-343, 2014. ,
Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy, J Am Soc Nephrol, vol.24, pp.1323-1329, 2013. ,
Immunopathogenesis of membranous nephropathy: An update, Semin Immunopathol, vol.36, pp.381-397, 2014. ,
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.2, pp.932-937, 2007. ,
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy, Kidney Int, vol.83, pp.940-948, 2013. ,
Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, vol.25, pp.1357-1366, 2014. ,
Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1735-1743, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00919117
Anti-phospholipase A? receptor antibodies correlate with clinical status in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.1286-1291, 2011. ,
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy, J Am Soc Nephrol, vol.22, pp.1543-1550, 2011. ,
Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition, J Am Soc Nephrol, vol.9, pp.2272-2282, 1998. ,
Aggressive lymphoma: Improving treatment outcome with rituximab, Anticancer Drugs, vol.13, pp.43-50, 2002. ,
Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome, J Am Soc Nephrol, vol.25, pp.850-863, 2014. ,
Stohl W: B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response, Ann Rheum Dis, vol.67, pp.1011-1016, 2008. ,
Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity, Arthritis Res Ther, vol.14, p.57, 2012. ,
,
Rituximab therapy in idiopathic membranous nephropathy: A 2-year study, Clin J Am Soc Nephrol, vol.5, pp.2188-2198, 2010. ,
Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy ,
, J Am Soc Nephrol
PREMIER) members: Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy, Progressive Renal Disease and Medical Informatics and Genomics Research, vol.117, pp.253-258, 2011. ,
Rituximab as preemptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies, Thromb Haemost, vol.101, pp.233-238, 2009. ,
Multivariable model-building. A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables, 2008. ,
Modelling continuous exposures with a 'spike' at zero: A new procedure based on fractional polynomials, Stat Med, vol.29, pp.1219-1227, 2010. ,
Analysing covariates with spike at zero: A modified FP procedure and conceptual issues, Biom J, vol.54, pp.686-700, 2012. ,
, Anti-phospholipase A 2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A 2 Receptor Autoantibodies, pp.2308-2311